Work

Plasma Alemtuzumab Levels at End of Treatment Correlate with Response and Response Duration in Patients with CLL Receiving Treatment for Residual Disease.

Year: 2008

Type: article

Source: Blood

DOI: 10.1182/blood.v112.11.2109.2109

Authors: William G Wierda, Thomas J Kipps, Michael J Keating, Jennifer R Brown, John G Gribben, Laura Z Rassenti, Andrew W Greaves, Donna Neuberg, Susan M O’Brien

Institutions: The University of Texas MD Anderson Cancer Center, University of California San Diego, Moores Cancer Center, Dana-Farber Cancer Institute

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2605714587

FWCI:

Cites:

Cited by:

Related to: 10